CEO Peter Lau expresses confidence in Horwath's understanding of FARO and his execution abilities, making him the ideal CFO. Horwath is eager for the opportunity and anticipates collaborating with Lau to expand the business.
FARO Technologies manages a reasonable debt load due to its net cash position, but its slow growth rate, negative free cash flow and lack of profitability bring skepticism about its future prospects.
Gainers: •$Okta (OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo (STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics (TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals (AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
Faro Technologies Stock Forum
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
No comment yet